Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety

References

• El SeragHBRudolphKLHepatocellular carcinoma: epidemiology and molecular carcinogenesisGastroenterology20071322557257617570226
   PubMed Web of Science ®Google Scholar
• BruixJLlovetJMPrognostic prediction and treatment strategy in hepatocellular carcinomaHepatology20023551952411870363
   PubMed Web of Science ®Google Scholar
• LlovetJMBurroughsABruixJHepatocellular carcinomaLancet20033621907191714667750
   PubMed Web of Science ®Google Scholar
• LlovetJMBruCBruixJPrognosis of hepatocellular carcinoma: the BCLC staging classificationSemin Liver Dis19991932933810518312
   PubMed Web of Science ®Google Scholar
• Bottsford-MillerJNColemanRLSoodAKResistance and escape from antiangiogenesis therapy: clinical implications and future strategiesJ Clin Oncol2012304026403423008289
   PubMed Web of Science ®Google Scholar
• FornerAVilanaRAyusoCDiagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinomaHepatology2008479710418069697
   PubMed Web of Science ®Google Scholar
• BruixJShermanMManagement of hepatocellular carcinomaHepatology2005421208123616250051
   PubMed Web of Science ®Google Scholar
• WilhelmSCarterCLynchMDiscovery and development of sorafenib: a multikinase inhibitor for treating cancerNat Rev Drug Discov2006583584417016424
   PubMed Web of Science ®Google Scholar
• AvilaMABerasainCSangroBPrietoJNew therapies for hepatocellular carcinomaOncogene2006253866388416799628
   PubMed Web of Science ®Google Scholar
• BruixJSalaMLlovetJMChemoembolization for hepatocellular carcinomaGastroenterology2004127S179S18815508083
   PubMed Web of Science ®Google Scholar
• LlovetJMBruixJUnresectable hepatocellular carcinoma: meta-analysis of arterial embolizationRadiology200423030030114695404
   PubMed Web of Science ®Google Scholar
• De LopeCRTremosiniSFornerAReigMBruixJManagement of HCCJ Hepatol201256SupplS75S8722300468
   PubMed Web of Science ®Google Scholar
• FernandezMSemelaDBruixJColleIPinzaniMBoschJAngiogenesis in liver diseaseJ Hepatol20095060462019157625
   PubMed Web of Science ®Google Scholar
• WangBXuHGaoZQNingHFSunYQCaoGWIncreased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolizationActa Radiol20084952352918568538
   PubMed Web of Science ®Google Scholar
• MoonWSRhyuKHKangMJOverexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?Mod Pathol20031655255712808060
   PubMed Web of Science ®Google Scholar
• YamaguchiRYanoHIemuraAOgasawaraSHaramakiMKojiroMExpression of vascular endothelial growth factor in human hepatocellular carcinomaHepatology19982868779657098
   PubMed Web of Science ®Google Scholar
• ChaoYLiCPChauGYPrognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgeryAnn Surg Oncol20031035536212734082
   PubMed Web of Science ®Google Scholar
• PoonRTLauCPHoJWYuWCFanSTWongJTissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinomaClin Cancer Res200395339534514614019
   PubMed Web of Science ®Google Scholar
• PoonRTHoJWTongCSLauCNgIOFanSTPrognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinomaBr J Surg2004911354136015376182
   PubMed Web of Science ®Google Scholar
• TorimuraTUenoTKinMOverexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinomaJ Hepatol20044079980715094228
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med200835937839018650514
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKSchwartzLRicciSPhase II study of sorafenib in patients with advanced hepatocellular carcinomaJ Clin Oncol2006244293430016908937
   PubMed Web of Science ®Google Scholar
• FuruseJIshiiHNakachiKSuzukiEShimizuSNakajimaKPhase I study of sorafenib in Japanese patients with hepatocellular carcinomaCancer Sci20089915916517953709
   PubMed Web of Science ®Google Scholar
• YauTChanPNgKKPhase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor responseCancer200911542843619107763
   PubMed Web of Science ®Google Scholar
• WornsMAWeinmannAPfingstKSafety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisJ Clin Gastroenterol20094348949519247201
   PubMed Web of Science ®Google Scholar
• WelkerMWLubomierskiNGogCEfficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditionsJ Chemother20102220521120566428
   PubMed Web of Science ®Google Scholar
• RimassaLPressianiTBoniCA phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinomaOncologist20131837938023580239
   PubMed Web of Science ®Google Scholar
• ChengAKangYLinDPhase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)J Clin Oncol201129Suppl4000
   Web of Science ®Google Scholar
• CainapCQinSHuangWTPhase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)J Clin Oncol201331Suppl249
   Web of Science ®Google Scholar
• FrenchDMLinBCWangMTargeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse modelsPloS One20127e3671322615798
   PubMed Web of Science ®Google Scholar
• CaiZZhangYBorzilleriRMDiscovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth faJ Med Chem2008511976198018288793
   PubMed Web of Science ®Google Scholar
• FinnRSKangYKMulcahyMPhase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinomaClin Cancer Res2012182090209822238246
   PubMed Web of Science ®Google Scholar
• ParkJWFinnRSKimJSPhase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinomaClin Cancer Res2011171973198321349999
   PubMed Web of Science ®Google Scholar
• LlovetJMDecaensTRaoulJLBrivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS studyJ Hepatol201256SupplS549
   Web of Science ®Google Scholar
• JohnsonPQinSParkJWBrivanib (BRI) versus sorafenib (SOR) as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma (HCC): results from the phase 3 BRISK-FL studyHepatology201256Suppl15191520
   Google Scholar
• RossMASanderCMKleebTBWatkinsSCStolzDBSpatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liverHepatology2001341135114811732003
   PubMed Web of Science ®Google Scholar
• VoglTJNaguibNNNour-EldinNEReview on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indicationsEur J Radiol20097250551618835117
   PubMed Web of Science ®Google Scholar
• LlovetJMRealMIMontanaXArterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialLancet20023591734173912049862
   PubMed Web of Science ®Google Scholar
• PoonRTLauCYuWCFanSTWongJHigh serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective studyOncol Rep2004111077108415069550
   PubMed Web of Science ®Google Scholar
• LiXFengGSZhengCSZhuoCKLiuXExpression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor levelWorld J Gastroenterol2004102878288215334691
   PubMed Web of Science ®Google Scholar
• ShimJHParkJWKimJHAssociation between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patientsCancer Sci2008992037204419016764
   PubMed Web of Science ®Google Scholar
• LeelawatKLaisupasinPKiatdilokrutAThe effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after tran-scatheter arterial chemoembolization (TACE)J Med Assoc Thai2008911539154318972897
   PubMedGoogle Scholar
• XiongZPYangSRLiangZYAssociation between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinomaHepatobiliary Pancreat Dis Int2004338639015313674
   PubMedGoogle Scholar
• SekiTTamaiTIkedaKRapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percu-taneous radiofrequency ablation in the primary tumour regionEur J Gastroenterol Hepatol20011329129411293452
   PubMed Web of Science ®Google Scholar
• ErhardtAKolligsFTDollingerMFirst-in-men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma – interim analysis of the SOCRATES trialHepatology200950SupplA1080
   Google Scholar
• ParkJWKohYHKimHBPhase II study of concurrent transar-terial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinomaJ Hepatol2012561336134222314421
   PubMed Web of Science ®Google Scholar
• DuanFWangMQLiuFYWangZJSongPWangYSorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasisAsia Pac J Clin Oncol2012815616322524574
   PubMed Web of Science ®Google Scholar
• TanWFQiuZQYuYSorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantationActa Pharmacol Sin2010311643164821102481
   PubMed Web of Science ®Google Scholar
• QuXDChenCSWangJHThe efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinomaBMC Cancer20121226322721173
   PubMed Web of Science ®Google Scholar
• ChungYHHanGYoonJHInterim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoem-bolization) with sorafenib in patients with hepatocellular carcinoma trialInt J Cancer20131322448245823129123
   PubMed Web of Science ®Google Scholar
• BaiWWangYJZhaoYSorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching studyJ Dig Dis20131418119023324079
   PubMed Web of Science ®Google Scholar
• HanGYangJShaoGSorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trialFuture Oncol2013940341023469975
   PubMed Web of Science ®Google Scholar
• ZhaoYWangWJGuanSSorafenib combined with transarte-rial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patientsAnn Oncol2013241786179223508822
   PubMed Web of Science ®Google Scholar
• DufourJFHoppeHHeimMHContinuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I studyOncologist2010151198120421036880
   PubMed Web of Science ®Google Scholar
• GaoSYangZZhengZDoxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysisHepatogastroenterology201360
   Google Scholar
• ReyesDKAzadNKamelIRPhase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma (HCC): interim safety and efficacy analysisHepatology200950Suppl6A7A19437494
   PubMed Web of Science ®Google Scholar
• LencioniRLlovetJHanGSorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trialJ Clin Oncol201230SupplLBA154
   Web of Science ®Google Scholar
• BurrelMReigMFornerASurvival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial designJ Hepatol2012561330133522314428
   PubMed Web of Science ®Google Scholar
• GeraldDChintharlapalliSAugustinHBenjaminLAngiopoietin-2: an attractive target for improved antiangiogenic tumor therapyCancer Res2013731649165723467610
   PubMed Web of Science ®Google Scholar
• ChristensenJGBurrowsJSalgiaRc-Met as a target for human cancer and characterization of inhibitors for therapeutic interventionCancer Lett200522512615922853
   PubMed Web of Science ®Google Scholar
• Danilkovitch-MiagkovaAZbarBDysregulation of Met receptor tyrosine kinase activity in invasive tumorsJ Clin Invest200210986386711927612
   PubMed Web of Science ®Google Scholar
• GherardiEBirchmeierWBirchmeierCVande WoudeGTargeting MET in cancer: rationale and progressNat Rev Cancer2012128910322270953
   PubMed Web of Science ®Google Scholar
• KondoSOjimaHTsudaHClinical impact of c-Met expression and its gene amplification in hepatocellular carcinomaInt J Clin Oncol20131820721322218908
   PubMed Web of Science ®Google Scholar
• Kaposi-NovakPLeeJSGòmez-QuirozLCoulouarnCFactorVMThorgeirssonSSMet-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotypeJ Clin Invest20061161582159516710476
   PubMed Web of Science ®Google Scholar
• UekiTFujimotoJSuzukiTYamamotoHOkamotoEExpression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinomaHepatology1997256196239049208
   PubMed Web of Science ®Google Scholar
• WhittakerSMaraisRZhuAXThe role of signaling pathways in the development and treatment of hepatocellular carcinomaOncogene2010294989500520639898
   PubMed Web of Science ®Google Scholar
• WelkerMWTrojanJAnti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectivesWord J Gastroenterol20111730753081
   Web of Science ®Google Scholar
• O’NeilBHWilliams-GoffLWKauhJA phase II study of AZD6244 in advanced or metastatic hepatocellular carcinomaJ Clin Oncol200927Supple15574
   Google Scholar
• SchwartzJDSchwartzMLehrerDBevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal veinJ Clin Oncol2006244144
   Web of Science ®Google Scholar
• SiegelABCohenEIOceanAPhase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinomaJ Clin Oncol2008262992299818565886
   PubMed Web of Science ®Google Scholar
• BoigeVMalkaDBourredjemAEfficacy, safety, and biomark-ers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinomaOncologist2012171063107222707516
   PubMed Web of Science ®Google Scholar
• KimGPMahoneyMRSzydloDAn international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaInvest New Drugs20123038739420839030
   PubMed Web of Science ®Google Scholar
• GruenwaldVWilkensLGebelMA phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final resultsJ Clin Oncol200725Suppl4598
   Google Scholar
• ZhuAXStuartKBlaszkowskyLSPhase 2 study of cetux-imab in patients with advanced hepatocellular carcinomaCancer200711058158917583545
   PubMed Web of Science ®Google Scholar
• PhilipPAMahoneyMRAllmerCPhase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancerJ Clin Oncol2005236657666316170173
   PubMed Web of Science ®Google Scholar
• ThomasMBChadhaRGloverKPhase 2 study of erlotinib in patients with unresectable hepatocellular carcinomaCancer20071101059106717623837
   PubMed Web of Science ®Google Scholar
• ShiahHSChenCYDaiCYRandomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinomaAliment Pharmacol Ther201337627323134470
   PubMed Web of Science ®Google Scholar
• ZhuAXAbramsTAMiksadRPhase 1/2 study of everolimus in advanced hepatocellular carcinomaCancer20111175094510221538343
   PubMed Web of Science ®Google Scholar
• O’DwyerPJGiantonioBJLevyDEFitzgeraldDBBensonABGefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group’s study E1203J Clin Oncol200624Suppl414316896003
   PubMed Web of Science ®Google Scholar
• LinAYFisherGASoSTangCLevittLPhase II study of ima-tinib in unresectable hepatocellular carcinomaAm J Clin Oncol200831848818376233
   PubMed Web of Science ®Google Scholar
• Bekaii-SaabTMarkowitzJPrescottNA multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomasClin Cancer Res2009155895590119737952
   PubMed Web of Science ®Google Scholar
• RamanathanRKBelaniCPSinghDAA phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerCancer Chemother Pharmacol20096477778319169683
   PubMed Web of Science ®Google Scholar
• TohHCChenPJCarrBIPhase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinomaCancer201311938038722833179
   PubMed Web of Science ®Google Scholar
• RizellMAnderssonMCahlinCHafstromLOlaussonMLindnerPEffects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancerInt J Clin Oncol200813667018307022
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol200910253419095497
   PubMed Web of Science ®Google Scholar
• KudoMImanakaKChidaNPhase III study of sorafenib after tran-sarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEur J Cancer2011472117212721664811
   PubMed Web of Science ®Google Scholar
• HodaDCatherineCStrosbergJPhase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC)Presented at: 2008 Gastrointestinal Cancers SymposiumJanuary 25–27, 2008Orlando, FL
   Google Scholar
• ZhuAXSahaniDVDudaDGEfficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyJ Clin Oncol2009273027303519470923
   PubMed Web of Science ®Google Scholar
• FaivreSRaymondEBoucherESafety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II studyLancet Oncol20091079480019586800
   PubMed Web of Science ®Google Scholar
• KoeberleDMontemurroMSamarasPContinuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)Oncologist20101528529220203173
   PubMed Web of Science ®Google Scholar
• WörnsMASchuchmannMDüberCOttoGGallePRWeinmannASunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatmentOncology201079859221071995
   PubMed Web of Science ®Google Scholar
• BaroneCBassoMBiolatoMA phase II study of suni-tinib in advanced hepatocellular carcinomaDig Liver Dis Epub2112013
   Google Scholar
• PinterMWichlasMSchmidKThalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trialEur J Gastroenterol Hepatol2008201012101918787470
   PubMed Web of Science ®Google Scholar
• SantoroASimonelliMRodriguez-LopeCA phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosisBr J Cancer2013108212423287988
   PubMed Web of Science ®Google Scholar
• SantoroARimassaLBorbathITivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyLancet Oncol201314556323182627
   PubMed Web of Science ®Google Scholar
• KanaiFYoshidaHTateishiRA phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinomaCancer Chemother Pharmacol20116731532420390419
   PubMed Web of Science ®Google Scholar
• HsuCYangTSHuoTIVandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled studyJ Hepatol2012561097110322245891
   PubMed Web of Science ®Google Scholar
• BrittenCDGomesASWainbergZATransarterial chemoem-bolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot studyBMC Cancer2012121622244160
   PubMed Web of Science ®Google Scholar
• BuijsMReyesDKPawlikTMPhase 2 trial of concurrent beva-cizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinomaCancer20131191042104923132335
   PubMed Web of Science ®Google Scholar
• PawlikTMReyesDKCosgroveDKamelIRBhagatNGeschwindJ-FHPhase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinomaJ Clin Oncol2011293960396721911714
   PubMed Web of Science ®Google Scholar
• CabreraRPannuDSCaridiJThe combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinomaAliment Pharmacol Ther20113420521321605146
   PubMed Web of Science ®Google Scholar
• ChowPKPoonDWinKMMulticenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: the Asia-Pacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05)J Clin Oncol201028Suppl4072
   Web of Science ®Google Scholar
• ErhardtAKolligsFTDollingerMSorafenib plus TACE for the treatment of advanced hepatocellular carcinoma – final results of the SOCRATES trialJ Clin Oncol201129Suppl4107
   Web of Science ®Google Scholar
• WuJBXuGJLuYSEfficacy of transcatheter arterial chemoembolization (TACE) combined with sorafenib in the treatment of advanced hepatocellular carcinomaAfr J Pharm Pharmacol2012625152519
   Google Scholar
• SieghartWPinterMReiseggerMConventional transarte-rial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot studyEur Radiol2012221214122322215073
   PubMed Web of Science ®Google Scholar
• HsuCHYangTSHsuCEfficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinomaBr J Cancer201010298198620160718
   PubMed Web of Science ®Google Scholar
• SunWSohalDHallerDGPhase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaCancer20111173187319221264839
   PubMed Web of Science ®Google Scholar
• ThomasMBMorrisJSChadhaRPhase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinomaJ Clin Oncol20092784385019139433
   PubMed Web of Science ®Google Scholar
• KasebAOGarrett-MayerEMorrisJSEfficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trialOncology201282677422327795
   PubMed Web of Science ®Google Scholar
• YauTWongHChanPPhase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory diseaseInvest New Drugs2012302384239022402942
   PubMed Web of Science ®Google Scholar
• PhilipPAMahoneyMRHolenKDPhase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancerCancer20121182424243021953248
   PubMed Web of Science ®Google Scholar
• GovindarajanRSiegelEMakhoulIWilliamsonSBevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinomaAm J Clin Oncol20123625425722643560
   PubMed Web of Science ®Google Scholar
• TreiberGWexTSchneiderGTreatment of advanced or metastatic hepatocellular cancer (HCC): final clinical results of a single-arm phase II study of bevacizumab and everolimusJ Clin Oncol201230Suppl4107
   Google Scholar
• ZhuAXBlaszkowskyLSRyanDPPhase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinomaJ Clin Oncol2006241898190316622265
   PubMed Web of Science ®Google Scholar
• BerlinJDPowellMESuYBortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): a phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlatesJ Clin Oncol200826Suppl4592
   Google Scholar
• SanoffHBernardSGoldbergRPhase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinomaGastrointest Cancer Res20114788322043322
   PubMedGoogle Scholar
• LouafiSBoigeVDucreuxMGemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II studyCancer20071091384139017330837
   PubMed Web of Science ®Google Scholar
• AsnaciosAFartouxLRomanoOGemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 studyCancer20081122733273918412149
   PubMed Web of Science ®Google Scholar
• ChioreanEGRamasubbaiahRYuMPhase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101Oncologist2012171322210086
   PubMed Web of Science ®Google Scholar
• LuelmoSOsantoSWeijlNPhase II study of everolimus and capecitabine in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). Results of the first 10 patients includedAnn Oncol201223Suppl1674
   Google Scholar
• KnoxJJChenXEFeldRA phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)Invest New Drugs20082619319418060598
   PubMed Web of Science ®Google Scholar
• YauTChanPPangRNgKFanSTPoonRTPhase 1–2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinomaCancer20101165022502920629034
   PubMed Web of Science ®Google Scholar
• PetriniILencioniMRicasoliMPhase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinomaCancer Chemother Pharmacol20126977378022033636
   PubMed Web of Science ®Google Scholar
• RichlyHSchultheisBAdamietzIACombination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trialEur J Cancer20094557958719101137
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKJohnsonPKnoxJJDoxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trialJAMA20103042154216021081728
   PubMed Web of Science ®Google Scholar
• DimaGLuciaMLa GattutaGPerspective phase II study of combination sorafenib plus mitomycin-c in the treatment of advanced hepatocellular carcinoma (HCC)Ann Oncol200919Suppl49
   Google Scholar
• PreteSDMontellaLCaragliaMSorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II SoLAR studyCancer Chemother Pharmacol20106683784420041325
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKChanSLLinCCPR-104 plus sorafenib in patients with advanced hepatocellular carcinomaCancer Chemother Pharmacol20116853954521594722
   PubMed Web of Science ®Google Scholar
• BitzerMHorgerMGantenTEfficacy, safety, toler-ability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC)J Clin Oncol201230Suppl4115
   Google Scholar
• ShenYShaoYHsuCPhase II study of sorafenib plus tegafur/ uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC)J Clin Oncol200826Suppl15664
   Web of Science ®Google Scholar
• HsuCHShenYCLinZZPhase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinomaJ Hepatol20105312613120416968
   PubMed Web of Science ®Google Scholar
• HsuCLinZLeeKA phase II trial of thalidomide plus tegafur/ uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): final reportJ Clin Oncol200927Suppl15533
   Google Scholar
• ZhuAXFuchsCSClarkJWA phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinomaOncologist20051039239815967833
   PubMed Web of Science ®Google Scholar
• TaiWTChengALShiauCWDovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3Mol Cancer Ther20121145246322180308
   PubMed Web of Science ®Google Scholar
• ZhuAXRosmorducOEvansJSEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC)Ann Oncol201223SupplLBA2
   Google Scholar